The FDA clears ALLO's investigational new drug application to start clinical studies on its investigational CAR T product, ALLO-329, for autoimmune diseases.

Learn more about whether Catalyst Pharmaceuticals, Inc. or CRISPR Therapeutics AG is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

"This type of gene editing should also allow for the treatment of diseases whose origin is not genetic or whose origin cannot ...

Base editing utilizes enzymes to modify single amino acids at the most foundational unit of DNA, called a base.

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

CARGO Therapeutics, Inc. (CRGX – Research Report) received a Hold rating and price target from Chardan Capital analyst Geulah Livshits ...

The Cell Therapy Regenerative Medicine market is poised for significant growth, driven by advancements in technology and increasing acceptanc ...

Beyond Casgevy, CRISPR Therapeutics continues to advance its pipeline across multiple therapeutic areas. The company's allogeneic CAR-T cell therapy programs, particularly CTX112 for B-cell ...

CRISPR Therapeutics is developing CTX112 for both hematologic ... CTX112 is a next-generation, wholly-owned, allogeneic CAR T product candidate targeting Cluster of Differentiation 19, or CD19, which ...